| Name | Title | Contact Details |
|---|---|---|
Chris Brough |
Chief Technology Officer | Profile |
NDI Medical is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Beachwood, OH. To find more information about NDI Medical, please visit www.ndimedical.com
Hugh Chatham Memorial Hospital is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Hugh Chatham Memorial Hospital is based in Elkin, NC. You can find more information on Hugh Chatham Memorial Hospital at www.hughchatham.org
American Habilitation Svc is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
More than 65 academic medical centers use ARUP as their primary reference laboratory and ARUP also provides all laboratory services, including phlebotomy and support services, for the 490-bed University of Utah Hospitals and Clinics. ARUP's 1,700
Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.